Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453545 | 0.91 | HDAC1 (0.48) | HDAC1HDAC6CNR1PTPN7LMNA | |
| SCHEMBL5461697 | 0.89 | SMN1; SMN2 (0.46) | HDAC1HDAC6CNR1LMNACNR2 | |
| SCHEMBL14411477 | 0.86 | HDAC1 (0.59) | HDAC1HDAC6CNR1PTPN7LMNA | |
| SCHEMBL5463302 | 0.85 | CNR1 (0.48) | HDAC1HDAC6CNR1PTPN7LMNA | |
| SCHEMBL5463063 | 0.85 | HDAC1 (0.58) | HDAC1HDAC6CNR1PTPN7LMNA | |
| SCHEMBL5451115 | 0.84 | HDAC1 (0.57) | HDAC1HDAC6CNR1PTPN7LMNA | |
| SCHEMBL5446833 | 0.84 | CNR2 (0.47) | HDAC1HDAC6CNR1CNR2P2RX7 | |
| SCHEMBL14463901 | 0.81 | CNR2 (0.48) | HDAC1HDAC6CNR1CNR2 | |
| SCHEMBL5446450 | 0.81 | HDAC1 (0.54) | HDAC1HDAC6CNR1PTPN7LMNA | |
| SCHEMBL5446567 | 0.81 | L3MBTL1 (0.56) | CNR1LMNACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | HDAC1 147/4885HDAC6 292/4885CNR1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.